BRPI1015917A2 - antígenos de rsv recombinantes. - Google Patents
antígenos de rsv recombinantes.Info
- Publication number
- BRPI1015917A2 BRPI1015917A2 BRPI1015917A BRPI1015917A BRPI1015917A2 BR PI1015917 A2 BRPI1015917 A2 BR PI1015917A2 BR PI1015917 A BRPI1015917 A BR PI1015917A BR PI1015917 A BRPI1015917 A BR PI1015917A BR PI1015917 A2 BRPI1015917 A2 BR PI1015917A2
- Authority
- BR
- Brazil
- Prior art keywords
- rsv
- recombinant
- antigen
- respiratory syncytial
- syncytial virus
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 5
- 102000036639 antigens Human genes 0.000 title abstract 5
- 108091007433 antigens Proteins 0.000 title abstract 5
- 241000725643 Respiratory syncytial virus Species 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 230000013595 glycosylation Effects 0.000 abstract 1
- 238000006206 glycosylation reaction Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21996409P | 2009-06-24 | 2009-06-24 | |
| US33456810P | 2010-05-13 | 2010-05-13 | |
| PCT/EP2010/059008 WO2010149745A1 (en) | 2009-06-24 | 2010-06-24 | Recombinant rsv antigens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1015917A2 true BRPI1015917A2 (pt) | 2019-08-27 |
Family
ID=42670494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1015917A BRPI1015917A2 (pt) | 2009-06-24 | 2010-06-24 | antígenos de rsv recombinantes. |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US9492531B2 (OSRAM) |
| EP (1) | EP2445526B1 (OSRAM) |
| JP (2) | JP6062245B2 (OSRAM) |
| KR (1) | KR101696002B1 (OSRAM) |
| CN (1) | CN102481359B (OSRAM) |
| AU (2) | AU2010264688A1 (OSRAM) |
| BR (1) | BRPI1015917A2 (OSRAM) |
| CA (1) | CA2766211A1 (OSRAM) |
| CL (1) | CL2011003273A1 (OSRAM) |
| CO (1) | CO6480978A2 (OSRAM) |
| CR (1) | CR20120025A (OSRAM) |
| CY (1) | CY1117673T1 (OSRAM) |
| DK (1) | DK2445526T3 (OSRAM) |
| DO (1) | DOP2011000389A (OSRAM) |
| EA (1) | EA023054B1 (OSRAM) |
| ES (1) | ES2583257T3 (OSRAM) |
| HR (1) | HRP20160798T1 (OSRAM) |
| HU (1) | HUE028085T2 (OSRAM) |
| IL (1) | IL217013B (OSRAM) |
| MA (1) | MA33449B1 (OSRAM) |
| MX (1) | MX2012000035A (OSRAM) |
| PE (1) | PE20121541A1 (OSRAM) |
| PL (1) | PL2445526T3 (OSRAM) |
| PT (1) | PT2445526T (OSRAM) |
| SG (1) | SG176829A1 (OSRAM) |
| SI (1) | SI2445526T1 (OSRAM) |
| UA (1) | UA111141C2 (OSRAM) |
| WO (1) | WO2010149745A1 (OSRAM) |
| ZA (1) | ZA201109199B (OSRAM) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2719406T3 (es) | 2007-12-24 | 2019-07-10 | Id Biomedical Corp Quebec | Antígenos recombinantes del VSR |
| HRP20160859T1 (hr) * | 2008-12-09 | 2016-09-23 | Novavax, Inc. | Modificirani proteini rsv f i postupci njihove upotrebe |
| AU2010264686A1 (en) | 2009-06-24 | 2012-01-19 | Glaxosmithkline Biologicals S.A. | Vaccine |
| EP4218799A1 (en) | 2009-07-15 | 2023-08-02 | GlaxoSmithKline Biologicals S.A. | Rsv f protein compositions and methods for making same |
| WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
| WO2012158613A1 (en) | 2011-05-13 | 2012-11-22 | Novartis Ag | Pre-fusion rsv f antigens |
| CN102294027A (zh) * | 2011-07-26 | 2011-12-28 | 昆明理工大学 | 一种呼吸道合胞病毒f2蛋白亚单位疫苗及其制备方法 |
| EP2752199A4 (en) | 2011-08-29 | 2015-04-29 | Univ Tokushima | RSV MUCOSA VACCINE |
| US10047116B2 (en) | 2011-10-03 | 2018-08-14 | Mx Adjuvac Ab | Nanoparticles, process for preparation and use thereof as carrier for amphipatic and hydrophobic molecules in fields of medicine including cancer treatment and food related compounds |
| CN102743750B (zh) * | 2012-07-09 | 2013-11-20 | 江苏省农业科学院 | 一种复方免疫增强剂、禽用疫苗及其制备方法 |
| SI2879702T1 (sl) | 2012-08-01 | 2020-02-28 | Bavarian Nordic A/S | Cepivo na osnovi rekombinantnega modificiranega virusa vakcinacije Ankara (MVA) proti respiratornemu sincitialnemu virusu (RSV) |
| US20140037680A1 (en) * | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
| WO2014024026A1 (en) | 2012-08-06 | 2014-02-13 | Glaxosmithkline Biologicals S.A. | Method for eliciting in infants an immune response against rsv and b. pertussis |
| US9738689B2 (en) | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
| WO2014160463A1 (en) | 2013-03-13 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prefusion rsv f proteins and their use |
| US9060975B2 (en) | 2013-03-14 | 2015-06-23 | Mucosis Bv | Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions |
| CN103204943B (zh) * | 2013-03-20 | 2014-07-23 | 中国科学院武汉病毒研究所 | 呼吸道合胞病毒F蛋白与Fc的融合蛋白及其用途 |
| BR112015025392A2 (pt) * | 2013-04-08 | 2017-10-10 | Medimmune Llc | composição de vacina e método de utilização |
| ME03442B (me) | 2013-04-25 | 2020-01-20 | Janssen Vaccines & Prevention Bv | Stabilizovani rastvorljivi pre-fuzioni rsv f polipeptidi |
| CN105408348B (zh) | 2013-06-17 | 2021-07-06 | 扬森疫苗与预防公司 | 稳定化的可溶性融合前rsv f多肽 |
| EP3030260A1 (en) * | 2013-08-05 | 2016-06-15 | GlaxoSmithKline Biologicals S.A. | Combination immunogenic compositions |
| US9388430B2 (en) * | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| CA2951430A1 (en) | 2014-06-13 | 2015-12-17 | Glaxosmithkline Biologicals Sa | Immunogenic combinations |
| EP3319634B1 (en) | 2015-07-07 | 2019-08-21 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
| EP3319633B1 (en) | 2015-07-07 | 2020-11-11 | Janssen Vaccines & Prevention B.V. | Vaccine against rsv |
| SG10202001389PA (en) | 2015-12-23 | 2020-04-29 | Pfizer | Rsv f protein mutants |
| EP3439672B1 (en) | 2016-04-05 | 2020-11-25 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f protein for use in the prophylaxis of rsv infection |
| IL262109B2 (en) | 2016-04-05 | 2023-04-01 | Janssen Vaccines Prevention B V | vaccine against rsv |
| IL264119B2 (en) | 2016-05-30 | 2023-04-01 | Janssen Vaccines Prevention B V | f proteins of rsv are stabilized before fusion |
| WO2017207477A1 (en) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
| CN107872643A (zh) * | 2016-09-23 | 2018-04-03 | 伊姆西Ip控股有限责任公司 | 用于视频监控系统的故障恢复方法和装置 |
| TWI683826B (zh) * | 2016-11-22 | 2020-02-01 | 國立臺灣大學 | 重組ｒｓｖ抗原 |
| GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
| US11306292B2 (en) | 2017-05-15 | 2022-04-19 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| WO2018211419A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| CA3061278A1 (en) | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
| US12016919B2 (en) | 2017-05-30 | 2024-06-25 | Glaxosmithkline Biologicals Sa | Methods for manufacturing an adjuvant |
| EP4295866A3 (en) | 2017-06-14 | 2024-03-20 | Virometix AG | Cyclic peptides for protection against respiratory syncytial virus |
| WO2019053109A1 (en) | 2017-09-15 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | METHOD FOR SAFE INDUCTION OF IMMUNITY AGAINST RSV |
| KR102700187B1 (ko) * | 2017-09-29 | 2024-08-28 | 에스케이바이오사이언스(주) | 가용성 변형 호흡기 융합세포 바이러스 (ｒｓｖ) ｆ 단백질 항원 |
| CA3083078A1 (en) | 2017-12-01 | 2019-06-06 | Glaxosmithkline Biologicals Sa | Saponin purification |
| BR112020020933A2 (pt) * | 2018-04-17 | 2021-04-06 | Curevac Ag | Moléculas de rna de rsv inovadoras e composições para vacinação |
| EP3833382A1 (en) | 2018-08-07 | 2021-06-16 | GlaxoSmithKline Biologicals S.A. | Processes and vaccines |
| MX2021005607A (es) | 2018-11-13 | 2021-06-30 | Janssen Vaccines & Prevention Bv | Proteinas f de prefusion del vrs estabilizadas. |
| US12465633B2 (en) | 2018-12-20 | 2025-11-11 | Virometix Ag | Lipopeptide building blocks and synthetic virus-like particles |
| US12121578B2 (en) | 2019-02-28 | 2024-10-22 | Km Biologics Co., Ltd. | RSV F/G chimeric vaccine |
| BR112021024363A2 (pt) | 2019-06-05 | 2022-03-22 | Glaxosmithkline Biologicals Sa | Purificação de saponina |
| JP2022060169A (ja) | 2020-10-02 | 2022-04-14 | ファイザー・インク | Ｒｓｖ ｆタンパク質生産のための細胞培養工程 |
| CN114685627A (zh) * | 2020-12-28 | 2022-07-01 | 广州更新生物医药科技有限公司 | 一种预防呼吸道合胞病毒的rAAV载体疫苗 |
| WO2022175477A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv fb antigens |
| EP4169513A1 (en) | 2021-10-19 | 2023-04-26 | GlaxoSmithKline Biologicals S.A. | Adjuvant composition comprising sting agonists |
| CN115772230A (zh) * | 2022-07-18 | 2023-03-10 | 青岛硕景生物科技有限公司 | 一种rsv重组抗原、其制备方法及应用 |
| IL319340A (en) | 2022-09-29 | 2025-05-01 | Pfizer | Immunogenic preparations containing RSV F protein truncation |
| TWI888970B (zh) | 2022-10-27 | 2025-07-01 | 美商輝瑞大藥廠 | Rna分子 |
| WO2024089634A1 (en) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Immunogenic compositions against influenza and rsv |
| EP4630049A1 (en) | 2022-12-11 | 2025-10-15 | Pfizer Inc. | Immunogenic compositions against influenza and rsv |
| US20240252614A1 (en) | 2023-01-18 | 2024-08-01 | Pfizer Inc. | Vaccines against respiratory diseases |
| WO2024193380A1 (zh) * | 2023-03-17 | 2024-09-26 | 成都威斯克生物医药有限公司 | 抗呼吸道合胞病毒感染的疫苗 |
| TW202515531A (zh) | 2023-07-07 | 2025-04-16 | 美商輝瑞股份有限公司 | 兩親性ｔｌｒ７／８佐劑及其用途 |
| EP4520334A1 (en) | 2023-09-07 | 2025-03-12 | Mnemo Therapeutics | Methods and compositions for improving immune response |
| WO2025052001A1 (en) | 2023-09-07 | 2025-03-13 | Mnemo Therapeutics | Methods and compositions for improving immune response |
| WO2025126071A1 (en) | 2023-12-14 | 2025-06-19 | Pfizer Inc. | Rna molecules |
| WO2025163460A2 (en) | 2024-01-30 | 2025-08-07 | Pfizer Inc. | Vaccines against respiratory diseases |
| WO2025186719A1 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Immunogenic compositions and uses thereof |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
| IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| US4707543A (en) | 1985-09-17 | 1987-11-17 | The United States Of America As Represented By The Secretary Of The Army | Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines |
| US5149650A (en) | 1986-01-14 | 1992-09-22 | University Of North Carolina At Chapel Hill | Vaccines for human respiratory virus |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US5726292A (en) | 1987-06-23 | 1998-03-10 | Lowell; George H. | Immuno-potentiating systems for preparation of immunogenic materials |
| AU617739B2 (en) | 1987-12-23 | 1991-12-05 | Pharmacia & Upjohn Company | Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus |
| US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| CA2138997C (en) | 1992-06-25 | 2003-06-03 | Jean-Paul Prieels | Vaccine composition containing adjuvants |
| JPH08505389A (ja) | 1993-01-08 | 1996-06-11 | ジ・アップジョン・カンパニー | ヒトｒｓウイルスのｆｇ糖蛋白質の精製および再生方法 |
| AU685443B2 (en) | 1993-03-23 | 1998-01-22 | Smithkline Beecham Biologicals (Sa) | Vaccine compositions containing 3-O deacylated monophosphoryl lipid A |
| US5961970A (en) | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
| ES2149340T3 (es) | 1993-11-17 | 2000-11-01 | Om Pharma | Disacaridos de glucosamina, metodo para su preparacion, composicion farmaceutica que los comprende, y su uso. |
| WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| FR2718452B1 (fr) | 1994-04-06 | 1996-06-28 | Pf Medicament | Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation. |
| DK0772619T4 (da) | 1994-07-15 | 2011-02-21 | Univ Iowa Res Found | Immunmodulatoriske oligonukleotider |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US5666153A (en) | 1995-10-03 | 1997-09-09 | Virtual Shopping, Inc. | Retractable teleconferencing apparatus |
| US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
| US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| US6764840B2 (en) | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6060308A (en) * | 1997-09-04 | 2000-05-09 | Connaught Laboratories Limited | RNA respiratory syncytial virus vaccines |
| KR100550132B1 (ko) | 1997-09-19 | 2006-02-08 | 와이어쓰 홀딩스 코포레이션 | 호흡 신시티아 바이러스의 부착 (지) 단백질에서 유도된펩티드 |
| GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
| HUP0102332A3 (en) | 1998-06-08 | 2002-11-28 | Sca Emballage France | Fast flattening packaging |
| DE69935330T2 (de) | 1998-06-30 | 2007-10-31 | Om Pharma | Neue acylierte pseudodipeptide, verfahren zu ihrer herstellung, und diese enthaltende pharmazeutische zusammensetzungen |
| CN101926993B (zh) | 1998-10-16 | 2013-12-04 | 史密丝克莱恩比彻姆生物有限公司 | 佐剂系统及疫苗 |
| US20040006242A1 (en) | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
| US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
| WO2001046127A1 (fr) | 1999-12-22 | 2001-06-28 | Om Pharma | Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise |
| AU2002223275A1 (en) | 2000-11-22 | 2002-06-03 | Biota Scientific Management Pty Ltd | A method of expression and agents identified thereby |
| SG141239A1 (en) | 2001-01-26 | 2008-04-28 | Selexis Sa | Matrix attachment regions and methods for use thereof |
| ATE489968T1 (de) | 2001-03-09 | 2010-12-15 | Id Biomedical Corp Quebec | Proteosom-liposaccharid-vakzine-adjuvans |
| US7157465B2 (en) | 2001-04-17 | 2007-01-02 | Dainippon Simitomo Pharma Co., Ltd. | Adenine derivatives |
| EP1719511B1 (en) | 2001-11-16 | 2008-12-10 | 3M Innovative Properties Company | N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide, a pharmaceutical composition comprising the same and use thereof |
| EP1592302A4 (en) | 2003-02-13 | 2007-04-25 | 3M Innovative Properties Co | METHODS AND COMPOSITIONS ASSOCIATED WITH IMMUNE RESPONSE MODIFIER COMPOUNDS AND TOLL-LIKE RECEPTOR 8 |
| US7368537B2 (en) | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
| EP2298898B1 (en) | 2003-10-24 | 2012-12-26 | Selexis S.A. | High efficiency gene transfer and expression in mammalian cells by a multiple transfection procedure of matrix attachment region sequences |
| FR2873378A1 (fr) | 2004-07-23 | 2006-01-27 | Pierre Fabre Medicament Sa | Complexes immunogenes, leur procede de preparation et leur utilisation dans des compositions pharmaceutiques |
| GB0422439D0 (en) | 2004-10-08 | 2004-11-10 | European Molecular Biology Lab Embl | Inhibitors of infection |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| WO2008061243A2 (en) * | 2006-11-16 | 2008-05-22 | Novavax, Inc. | Respiratory syncytial virus-virus like particle (vlps) |
| JP2010522540A (ja) | 2007-03-21 | 2010-07-08 | アイディー バイオメディカル コーポレイション オブ ケベック | キメラ抗原 |
| US20100261155A1 (en) | 2007-06-06 | 2010-10-14 | Nationwide Children's Hospital, Inc. | Methods and compositions relating to viral fusion proteins |
| ES2719406T3 (es) | 2007-12-24 | 2019-07-10 | Id Biomedical Corp Quebec | Antígenos recombinantes del VSR |
| WO2010006447A1 (en) | 2008-07-18 | 2010-01-21 | Id Biomedical Corporation Of Quebec | Chimeric respiratory syncytial virus polypeptide antigens |
| AU2010264686A1 (en) | 2009-06-24 | 2012-01-19 | Glaxosmithkline Biologicals S.A. | Vaccine |
-
2010
- 2010-06-24 WO PCT/EP2010/059008 patent/WO2010149745A1/en not_active Ceased
- 2010-06-24 US US13/378,391 patent/US9492531B2/en not_active Expired - Fee Related
- 2010-06-24 HR HRP20160798TT patent/HRP20160798T1/hr unknown
- 2010-06-24 ES ES10724879.1T patent/ES2583257T3/es active Active
- 2010-06-24 SG SG2011092319A patent/SG176829A1/en unknown
- 2010-06-24 KR KR1020127001782A patent/KR101696002B1/ko not_active Expired - Fee Related
- 2010-06-24 JP JP2012516746A patent/JP6062245B2/ja not_active Expired - Fee Related
- 2010-06-24 UA UAA201200714A patent/UA111141C2/uk unknown
- 2010-06-24 AU AU2010264688A patent/AU2010264688A1/en not_active Abandoned
- 2010-06-24 PL PL10724879T patent/PL2445526T3/pl unknown
- 2010-06-24 MX MX2012000035A patent/MX2012000035A/es active IP Right Grant
- 2010-06-24 DK DK10724879.1T patent/DK2445526T3/en active
- 2010-06-24 SI SI201031234A patent/SI2445526T1/sl unknown
- 2010-06-24 HU HUE10724879A patent/HUE028085T2/en unknown
- 2010-06-24 PE PE2011002168A patent/PE20121541A1/es not_active Application Discontinuation
- 2010-06-24 CN CN201080037770.3A patent/CN102481359B/zh not_active Expired - Fee Related
- 2010-06-24 MA MA34557A patent/MA33449B1/fr unknown
- 2010-06-24 PT PT107248791T patent/PT2445526T/pt unknown
- 2010-06-24 CA CA2766211A patent/CA2766211A1/en not_active Abandoned
- 2010-06-24 EP EP10724879.1A patent/EP2445526B1/en active Active
- 2010-06-24 EA EA201270063A patent/EA023054B1/ru not_active IP Right Cessation
- 2010-06-24 BR BRPI1015917A patent/BRPI1015917A2/pt not_active Application Discontinuation
-
2011
- 2011-12-14 ZA ZA2011/09199A patent/ZA201109199B/en unknown
- 2011-12-14 DO DO2011000389A patent/DOP2011000389A/es unknown
- 2011-12-15 IL IL217013A patent/IL217013B/en not_active IP Right Cessation
- 2011-12-22 CL CL2011003273A patent/CL2011003273A1/es unknown
- 2011-12-29 CO CO11181053A patent/CO6480978A2/es unknown
-
2012
- 2012-01-16 CR CR20120025A patent/CR20120025A/es unknown
-
2014
- 2014-07-03 AU AU2014203636A patent/AU2014203636C1/en not_active Ceased
-
2016
- 2016-01-14 JP JP2016005403A patent/JP2016128457A/ja active Pending
- 2016-06-21 CY CY20161100557T patent/CY1117673T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1015917A2 (pt) | antígenos de rsv recombinantes. | |
| EA201070794A1 (ru) | Рекомбинантные антигены rsv | |
| CY1123152T1 (el) | Τροποποιημενες πρωτεϊνες rsv f και μεθοδοι χρησης τους | |
| WO2018109220A3 (en) | Novel recombinant prefusion rsv f proteins and uses thereof | |
| CL2012000119A1 (es) | Polipeptido f de virus respiratorio sincicial recombinante, composicion inmunogenica que lo comprende, uso para la preparacion de un medicamento para la profilaxis contra dicho virus. | |
| PE20190420A1 (es) | Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas | |
| WO2009026397A3 (en) | Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods | |
| WO2007095318A3 (en) | Influenza antigens, vaccine compositions, and related methods | |
| MX385818B (es) | Proteínas f de rsv de prefusión y su uso. | |
| WO2010039224A3 (en) | Respiratory syncytial virus (rsv) sequences for protein expression and vaccines | |
| ECSP066681A (es) | Formas sólidas de anticuerpos anti-egfr | |
| MX2012000036A (es) | Vacuna. | |
| GEP20217260B (en) | Antibody neutralizing human respiratory syncytial virus | |
| WO2007064742A3 (en) | Identification of protective antigenic determinants of porcine reproductive and respiratory syndrome virus (prrsv) and uses thereof | |
| WO2006113214A3 (en) | Vaccine against pandemic strains of influenza viruses | |
| NZ627888A (en) | Materials and methods for respiratory disease control in canines | |
| WO2006115843A3 (en) | Nipah virus vaccines | |
| PH12021552648A1 (en) | Csfv subunit vaccine | |
| GEP201706766B (en) | Methods and compositions for vaccinating against staphylococcus aureus | |
| WO2008118487A3 (en) | Compositions and methods for incresing immunogenicity of glycoprotein vaccines | |
| WO2008124176A3 (en) | Soluble and membrane-anchored forms of lassa virus subunit proteins | |
| WO2009005917A3 (en) | Methods of treating measles infectious disease in mammals | |
| DE602004028512D1 (de) | Rekombinante vakzine gegen infektion mit dem japanischen enzephalitis-virus äjevü und verfahren davon | |
| WO2008027414A3 (en) | Novel p. falciparum vaccine proteins and coding sequences | |
| TR201905336T4 (tr) | Rekombinant rsv antijenleri. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |